PURPOSE: Promoter hypermethylation has been recently proposed as a means for head and neck squamous cell carcinoma (HNSCC) detection in salivary rinses. In a prospective study of a high-risk population, we showed that endothelin receptor type B (EDNRB) promoter methylation in salivary rinses is a useful biomarker for oral cancer and premalignancy. EXPERIMENTAL DESIGN: Using that cohort, we evaluated EDNRB methylation status and 8 additional genes. Clinical risk assessment by expert clinicians was conducted and compared with biomarker performance in the prediction of premalignant and malignant disease. Methylation status of 9 genes was analyzed in salivary rinses of 191 patients by quantitative methylation-specific PCR. RESULTS: HOXA9, EDNRB, and deleted in colorectal cancer (DCC) methylation were associated (P = 0.012; P < 0.0001; P = 0.0005) with premalignant or malignant disease. On multivariable modeling, histological diagnosis was only independently associated with EDNRB (P = 0.0003) or DCC (P = 0.004) methylation. A subset of patients received clinical risk classification (CRC) by expert clinicians based on lesion examination. CRC, DCC, and EDNRB were associated with diagnosis of dysplasia/cancer on univariate (P = 0.008; P = 0.026; P = 0.046) and multivariate analysis (P = 0.012; P = 0.037; P = 0.047). CRC identified dysplasia/cancer with 56% of sensitivity and 66% of specificity with a similar area under curve [AUC; 0.61, 95% confidence interval (CI) = 0.60-0.81] when compared to EDNRB and DCC combined AUC (0.60, 95% CI = 0.51-0.69), sensitivity of 46% and specificity of 72%. A combination of EDNRB, DCC, and CRC was optimal AUC (0.67, 95% CI = 0.58-0.76). CONCLUSIONS: EDNRB and/or DCC methylation in salivary rinses compares well to examination by an expert clinician in CRC of oral lesions. These salivary biomarkers may be particularly useful in oral premalignancy and malignancy screening in clinical care settings in which expert clinicians are not available.
PURPOSE: Promoter hypermethylation has been recently proposed as a means for head and neck squamous cell carcinoma (HNSCC) detection in salivary rinses. In a prospective study of a high-risk population, we showed that endothelin receptor type B (EDNRB) promoter methylation in salivary rinses is a useful biomarker for oral cancer and premalignancy. EXPERIMENTAL DESIGN: Using that cohort, we evaluated EDNRB methylation status and 8 additional genes. Clinical risk assessment by expert clinicians was conducted and compared with biomarker performance in the prediction of premalignant and malignant disease. Methylation status of 9 genes was analyzed in salivary rinses of 191 patients by quantitative methylation-specific PCR. RESULTS:HOXA9, EDNRB, and deleted in colorectal cancer (DCC) methylation were associated (P = 0.012; P < 0.0001; P = 0.0005) with premalignant or malignant disease. On multivariable modeling, histological diagnosis was only independently associated with EDNRB (P = 0.0003) or DCC (P = 0.004) methylation. A subset of patients received clinical risk classification (CRC) by expert clinicians based on lesion examination. CRC, DCC, and EDNRB were associated with diagnosis of dysplasia/cancer on univariate (P = 0.008; P = 0.026; P = 0.046) and multivariate analysis (P = 0.012; P = 0.037; P = 0.047). CRC identified dysplasia/cancer with 56% of sensitivity and 66% of specificity with a similar area under curve [AUC; 0.61, 95% confidence interval (CI) = 0.60-0.81] when compared to EDNRB and DCC combined AUC (0.60, 95% CI = 0.51-0.69), sensitivity of 46% and specificity of 72%. A combination of EDNRB, DCC, and CRC was optimal AUC (0.67, 95% CI = 0.58-0.76). CONCLUSIONS:EDNRB and/or DCC methylation in salivary rinses compares well to examination by an expert clinician in CRC of oral lesions. These salivary biomarkers may be particularly useful in oral premalignancy and malignancy screening in clinical care settings in which expert clinicians are not available.
Authors: Angela Di Vinci; Ida Casciano; Elena Marasco; Barbara Banelli; Gian Luigi Ravetti; Luana Borzì; Claudio Brigati; Alessandra Forlani; Alessandra Dorcaratto; Giorgio Allemanni; Gianluigi Zona; Renato Spaziante; Henning Gohlke; Giovanni Gardin; Domenico Franco Merlo; Vilma Mantovani; Massimo Romani Journal: J Cancer Res Clin Oncol Date: 2011-09-27 Impact factor: 4.553
Authors: S L Rosas; W Koch; M G da Costa Carvalho; L Wu; J Califano; W Westra; J Jen; D Sidransky Journal: Cancer Res Date: 2001-02-01 Impact factor: 12.701
Authors: R Guerrero-Preston; E Soudry; J Acero; M Orera; L Moreno-López; G Macía-Colón; A Jaffe; M Berdasco; C Ili-Gangas; P Brebi-Mieville; Y Fu; C Engstrom; R A Irizarry; M Esteller; W Westra; W Koch; J Califano; D Sidransky Journal: Cancer Prev Res (Phila) Date: 2011-05-10
Authors: Semra Demokan; Xiaofei Chang; Alice Chuang; Wojciech K Mydlarz; Jatinder Kaur; Peng Huang; Zubair Khan; Tanbir Khan; Kimberly L Ostrow; Mariana Brait; Mohammad O Hoque; Nanette J Liegeois; David Sidransky; Wayne Koch; Joseph A Califano Journal: Int J Cancer Date: 2010-11-15 Impact factor: 7.396
Authors: Marco Cianchetti; Anthony A Mancuso; Robert J Amdur; John W Werning; Jessica Kirwan; Christopher G Morris; William M Mendenhall Journal: Laryngoscope Date: 2009-12 Impact factor: 3.325
Authors: Scott M Langevin; Damaris Kuhnell; Liang Niu; Jacek Biesiada; Yuet-Kin Leung; Ranjan Deka; Aimin Chen; Mario Medvedovic; Karl T Kelsey; Susan Kasper; Xiang Zhang Journal: Epigenomics Date: 2019-06-19 Impact factor: 4.778
Authors: Daniela Russo; Francesco Merolla; Silvia Varricchio; Giovanni Salzano; Giovanni Zarrilli; Massimo Mascolo; Viviana Strazzullo; Rosa Maria Di Crescenzo; Angela Celetti; Gennaro Ilardi Journal: Biomed Rep Date: 2018-07-27
Authors: Scott M Langevin; Rondi A Butler; Melissa Eliot; Michael Pawlita; Jennifer Z J Maccani; Michael D McClean; Karl T Kelsey Journal: Oral Oncol Date: 2014-09-18 Impact factor: 5.337
Authors: Jean-Philippe Foy; Curtis R Pickering; Vassiliki A Papadimitrakopoulou; Jaroslav Jelinek; Steven H Lin; William N William; Mitchell J Frederick; Jing Wang; Wenhua Lang; Lei Feng; Li Zhang; Edward S Kim; You H Fan; Waun K Hong; Adel K El-Naggar; J Jack Lee; Jeffrey N Myers; Jean-Pierre Issa; Scott M Lippman; Li Mao; Pierre Saintigny Journal: Cancer Prev Res (Phila) Date: 2015-09-04
Authors: Nataša Vasiljević; Dorota Scibior-Bentkowska; Adam R Brentnall; Jack Cuzick; Attila T Lorincz Journal: Gynecol Oncol Date: 2014-02-06 Impact factor: 5.482